9 March 2018

2017 Annual Report and Accounts and Notice of AGM

March 9, 2018, LONDON – Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, is pleased to confirm that a hard copy of the A…

Read more

9 March 2018

Grant of Options and RSUs and PDMR Dealings

March 9, 2018, LONDON – Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that it granted the following options…

Read more

9 March 2018

Grant of Options and RSUs and PDMR Dealings

March 9, 2018, LONDON - Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that it granted the following options over…

Read more

8 March 2018

PDMR Dealing

March 8, 2018, LONDON – Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on March 7, 2018, Dr. Jan-Ander…

Read more

8 March 2018

1st Quarter Results

LONDON, March 08, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on March 7, 2018,…

Read more

2 March 2018

Second Price Monitoring Extension

A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes.

Read more

2 March 2018

Price Monitoring Extension

The auction call period has been extended in this security by 5 minutes.

Read more

2 March 2018

Second Price Monitoring Extn

Second Price Monitoring Extension

Read more

2 March 2018

Price Monitoring Extension

Price Monitoring Extension

Read more

30 November 2017

Block listing Interim Review

LONDON, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, provides the following update on it…

Read more

Targeting unmet needs

384m people worldwide suffer from COPD and 37 years is the median life expectancy of CF patients

Read more about COPD and CF in the unmet needs section of this website

Go

The Lancet Respiratory Medicine

Peer-reviewed paper in the Lancet's highly-respected medication journal

Basic & Clinical Pharmacology & Toxicology

Peer-reviewed publication on dual PDE3/4 inhibitors as novel treatments for COPD

Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us